Lactobacillus GG is associated with mucin genes expressions in type 2 diabetes mellitus: a randomized, placebo-controlled trial.
Purpose: Recent studies indicate that dysbiosis of gut microbiota and low-grade inflammation are important pathogenic determinants of type two diabetes mellitus (T2DM). The aim of this study is to investigate the effects of Lactobacillus GG on glycemic control, lipid profile, inflammatory parameters...
| Publicado en: | European Journal of Nutrition Vol. 62; no. 5; pp. 2155 - 2165 |
|---|---|
| Autores principales: | , , , , , , , |
| Formato: | research tables/charts randomized controlled trial Journal Article |
| Publicado: |
Springer Nature
Aug2023
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=164947187&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 164947187 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 14366207 CR0 jtl: European Journal of Nutrition issn: 14366207 maglogo: N pubinfo: dt: Aug2023 vid: 62 iid: 5 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 164947187 162777079 164947187 164947187 10.1007/s00394-023-03139-3 164947187 ppf: 2155 ppct: 10 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Lactobacillus GG is associated with mucin genes expressions in type 2 diabetes mellitus: a randomized, placebo-controlled trial. aug: au: Eliuz Tipici, Beyza Coskunpinar, Ender Altunkanat, Derya Cagatay, Penbe Omer, Beyhan Palanduz, Sukru Satman, Ilhan Aral, Ferihan affil: Department of Pediatrics, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey sug: subj: Probiotics Therapeutic Use Lactobacillus Metabolism Diabetes Mellitus, Type 2 Drug Therapy Glycemic Control Lipids Inflammation Mediators Gene Expression Human Randomized Controlled Trials Random Assignment Turkiye Middle Age Male Female Adult Anthropometry Diet Records Blood Glucose Blood Proteins Dietary Fiber Cholesterol Funding Source Middle Aged: 45-64 years Adult: 19-44 years Male Female ab: Purpose: Recent studies indicate that dysbiosis of gut microbiota and low-grade inflammation are important pathogenic determinants of type two diabetes mellitus (T2DM). The aim of this study is to investigate the effects of Lactobacillus GG on glycemic control, lipid profile, inflammatory parameters, and some gene expression levels in individuals with T2DM. Methods: In a randomized, placebo-controlled trial, 34 women, aged 30–60 years with T2DM consumed daily probiotics or placebo for 8 weeks. The probiotic group consumed 10 × 109 Cfu/day Lactobacillus rhamnosus GG ATCC 53,103 (LGG), approved by the TR Ministry of Food, Agriculture, and Livestock. Anthropometric measurements, food diary, fasting blood, and fecal samples were taken at baseline and post-treatment. Results: Fasting blood glucose was significantly decreased in probiotic (p = 0.049) and placebo (p = 0.028), but there was no difference between the groups. In the probiotic group, no significant difference was observed in HbA1c, fructosamine, lipid profile, and inflammatory variables compared to baseline. In this group, with LGG supplementation, mucin 2 and 3A (MUC2 and MUC3A) gene expressions increased more than ninefolds (p = 0.046 and p = 0.008, respectively) at post-treatment. Meanwhile, there was no significant change in any of the gene expressions in the placebo group. There was no significant difference in energy, protein, dietary fiber, and cholesterol intakes between placebo and probiotic groups during the study. However, daily fat intake (p = 0.003), body weight (p = 0.014), and body fat (p = 0.015) in the probiotic group were significantly decreased. Conclusion: In this study, the effects of a single probiotic strain were investigated for 8 weeks. At the end of the study, although there was no finding that clearly reflected on the glycemic parameters of T2DM, its beneficial effects on the expression of mucin genes, which are responsible for weight loss and protection of intestinal barrier functions, cannot be denied. Further studies are needed to reveal the importance of these findings. Clinical trial registration: ID: NCT05066152, October 4, 2021 retrospectively registered in ClinicalTrials.gov PRS web site. pubtype: Academic Journal doctype: research tables/charts randomized controlled trial Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|